US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

0.6150

+0.02504.24%

Post-market: 0.64770.0327+5.32%19:45 EST

Volume:101.24K

Turnover:63.52K

Market Cap:12.81M

PE:-2.01

High:0.6518

Open:0.6000

Low:0.5951

Close:0.5900

52wk High:2.11

52wk Low:0.4000

Shares:20.82M

Float Shares:1.55M

Volume Ratio:0.91

T/O Rate:6.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3056

EPS(LYR):-0.2292

ROE:-92.07%

ROA:-53.59%

PB:1.67

PE(LYR):-2.68

Loading ...

Overview Company News Filings

Kairos Pharma to Present at DealFlow Discovery Conference in Atlantic City

Kairos Pharma Ltd - May Offer up to $75 Mln in Securities - SEC Filing

THOMSON REUTERS

Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Secures Department of Defense Funding for ENV205 Cancer Drug Research

Kairos Pharma Provides Shareholder Update

THOMSON REUTERS

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Reports Positive Phase 2 Results for ENV-105 in Advanced Prostate Cancer

Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors

Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma to Present at ESMO Congress 2025

Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025

Kairos Pharma to Present Positive Safety and Efficacy Data From Phase 2 Prostate Cancer Trial at Esmo 2025

THOMSON REUTERS

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Reports Positive Phase 2 Trial Results

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of Env105 in Advanced Prostate Cancer With Median Progression Free Survival of Over One Year

THOMSON REUTERS

Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation

Kapa Gold Inc. Secures $710,520 Through Warrant Exercise to Bolster Operations

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KAPA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":0.615,"timestamp":1770411600000,"preClose":0.59,"halted":0,"volume":101239,"hourTrading":{"tag":"盘后","latestPrice":0.6477,"preClose":0.615,"latestTime":"19:45 EST","volume":199,"amount":127.3657,"timestamp":1770425117065,"change":0.0327,"changeRate":0.053171,"amplitude":0},"delay":0,"changeRate":0.04237288135593224,"floatShares":1550000,"shares":20821353,"eps":-0.30563,"marketStatus":"Market Closed","change":0.025,"latestTime":"02-06 16:00:00 EST","open":0.6,"high":0.6518,"low":0.5951,"amount":63515.958864,"amplitude":0.096102,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.30563,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1717992000000,"exchange":"AMEX","adjPreClose":0.59,"preHourTrading":{"tag":"盘前","latestPrice":0.6032,"preClose":0.59,"latestTime":"09:27 EST","volume":865,"amount":514.924985,"timestamp":1770388027994,"change":0.0132,"changeRate":0.022373,"amplitude":0.022203},"postHourTrading":{"tag":"盘后","latestPrice":0.6477,"preClose":0.615,"latestTime":"19:45 EST","volume":199,"amount":127.3657,"timestamp":1770425117065,"change":0.0327,"changeRate":0.053171,"amplitude":0},"volumeRatio":0.9089440920772646},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":1550000,"roa":"-53.59%","roe":"-92.07%","lyrEps":-0.229208,"volumeRatio":0.9089440920772646,"shares":20821353,"dividePrice":0,"high":0.6518,"amplitude":0.096102,"preClose":0.59,"low":0.5951,"week52Low":0.4,"pbRate":"1.67","week52High":2.11,"institutionHeld":0,"latestPrice":0.615,"eps":-0.30563,"divideRate":0,"volume":101239,"delay":0,"ttmEps":-0.30563,"open":0.6,"prevYearClose":0.71,"prevWeekClose":0.6644,"prevMonthClose":0.6644,"prevQuarterClose":0.71,"fiveDayClose":0.6644,"twentyDayClose":0.97,"sixtyDayClose":0.928},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1743656400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2026-02-06","current":-2.012237,"percent":0.988539,"low":-25.607053,"twenty":-7.586816,"median":-5.063751,"eighty":-3.364521,"high":-2.140651,"avg":-5.712431,"sd":2.915353,"marketCap":12284598},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-20","current":-2.911286,"twenty":-8.578362,"median":-6.702263,"eighty":-4.758377,"marketCap":10311775},{"date":"2025-06-27","current":-3.282332,"twenty":-8.578362,"median":-6.467918,"eighty":-4.698397,"marketCap":11626021},{"date":"2025-07-03","current":-3.096809,"twenty":-8.578362,"median":-6.421049,"eighty":-4.598431,"marketCap":10968898},{"date":"2025-07-11","current":-3.382229,"twenty":-8.578362,"median":-6.327311,"eighty":-4.315248,"marketCap":11979856},{"date":"2025-07-18","current":-4.852143,"twenty":-8.578362,"median":-6.210138,"eighty":-4.078861,"marketCap":17186292},{"date":"2025-07-25","current":-4.424013,"twenty":-8.501541,"median":-6.156578,"eighty":-4.315248,"marketCap":15669854},{"date":"2025-08-01","current":-4.281779,"twenty":-8.456729,"median":-5.830571,"eighty":-4.144691,"marketCap":15166060},{"date":"2025-08-08","current":-4.566723,"twenty":-8.326712,"median":-5.698056,"eighty":-4.256377,"marketCap":16175333},{"date":"2025-08-15","current":-5.460044,"twenty":-8.265781,"median":-5.577408,"eighty":-4.144691,"marketCap":25722268},{"date":"2025-08-22","current":-5.151816,"twenty":-8.175816,"median":-5.56016,"eighty":-4.256377,"marketCap":24270205},{"date":"2025-08-29","current":-5.548109,"twenty":-8.117706,"median":-5.504045,"eighty":-4.350727,"marketCap":26137143},{"date":"2025-09-05","current":-6.825055,"twenty":-8.080211,"median":-5.554134,"eighty":-4.371339,"marketCap":32152835},{"date":"2025-09-12","current":-7.925871,"twenty":-8.146034,"median":-5.577408,"eighty":-4.403843,"marketCap":37338777},{"date":"2025-09-19","current":-5.90037,"twenty":-8.123413,"median":-5.684601,"eighty":-4.424013,"marketCap":27796645},{"date":"2025-09-26","current":-5.019718,"twenty":-8.080211,"median":-5.577408,"eighty":-4.452555,"marketCap":23647892},{"date":"2025-10-03","current":-5.063751,"twenty":-8.031527,"median":-5.554134,"eighty":-4.485854,"marketCap":23855329},{"date":"2025-10-10","current":-5.812305,"twenty":-7.985263,"median":-5.56016,"eighty":-4.525921,"marketCap":27381769},{"date":"2025-10-17","current":-5.151816,"twenty":-7.967725,"median":-5.531688,"eighty":-4.55855,"marketCap":24270205},{"date":"2025-10-24","current":-4.799555,"twenty":-7.967725,"median":-5.492822,"eighty":-4.58125,"marketCap":22610703},{"date":"2025-10-31","current":-5.019718,"twenty":-7.967725,"median":-5.46521,"eighty":-4.595432,"marketCap":23647892},{"date":"2025-11-07","current":-3.830837,"twenty":-7.967725,"median":-5.399832,"eighty":-4.525921,"marketCap":18047075},{"date":"2025-11-14","current":-3.48298,"twenty":-7.942613,"median":-5.371979,"eighty":-4.424013,"marketCap":16408318},{"date":"2025-11-21","current":-2.82458,"twenty":-7.922862,"median":-5.327946,"eighty":-4.230974,"marketCap":14298023},{"date":"2025-11-28","current":-3.42923,"twenty":-7.902108,"median":-5.296194,"eighty":-4.097795,"marketCap":17358761},{"date":"2025-12-05","current":-3.740193,"twenty":-7.855239,"median":-5.283914,"eighty":-3.903739,"marketCap":18932856},{"date":"2025-12-12","current":-3.331745,"twenty":-7.817744,"median":-5.203591,"eighty":-3.780288,"marketCap":16865295},{"date":"2025-12-19","current":-3.187781,"twenty":-7.79431,"median":-5.197038,"eighty":-3.655562,"marketCap":16136548},{"date":"2025-12-26","current":-3.052866,"twenty":-7.780249,"median":-5.190491,"eighty":-3.531486,"marketCap":15453608},{"date":"2026-01-02","current":-2.920419,"twenty":-7.780249,"median":-5.153702,"eighty":-3.48298,"marketCap":14783160},{"date":"2026-01-09","current":-3.989868,"twenty":-7.780249,"median":-5.151816,"eighty":-3.42923,"marketCap":20196712},{"date":"2026-01-16","current":-3.660807,"twenty":-7.780249,"median":-5.14469,"eighty":-3.42923,"marketCap":18531004},{"date":"2026-01-23","current":-3.208347,"twenty":-7.755842,"median":-5.119133,"eighty":-3.42923,"marketCap":16240655},{"date":"2026-01-30","current":-2.734499,"twenty":-7.661662,"median":-5.098261,"eighty":-3.381278,"marketCap":13842035},{"date":"2026-02-06","current":-2.426827,"twenty":-7.586816,"median":-5.063751,"eighty":-3.364521,"marketCap":12284598}],"updateTime":1770491016203},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604130681","title":"Kairos Pharma to Present at DealFlow Discovery Conference in Atlantic City","url":"https://stock-news.laohu8.com/highlight/detail?id=2604130681","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604130681?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:03","pubTimestamp":1768914221,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL2YMLd1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2603688444","title":"Kairos Pharma Ltd - May Offer up to $75 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603688444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603688444?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:01","pubTimestamp":1768302082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2584298239","title":"Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2584298239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584298239?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571322,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on Kairos Pharma, Ltd. yesterday and set a price target of $4.00. Jason McCarthy has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharmas-promising-clinical-developments-and-strategic-focus-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharmas-promising-clinical-developments-and-strategic-focus-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2584411089","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584411089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584411089?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:19","pubTimestamp":1763558340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 08:19 ET (13:19 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2580375354","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580375354","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580375354?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:41","pubTimestamp":1762267260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 09:41 ET (14:41 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2580317247","title":"Kairos Pharma Secures Department of Defense Funding for ENV205 Cancer Drug Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2580317247","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580317247?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261232,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has announced the receipt of Department of Defense funding for research related to ENV205, a new drug aimed at treating chemotherapy drug resistance and cachexia. The funding supports the continued advancement of ENV205 as part of Kairos Pharma's broader focus on developing innovative cancer therapeutics. There is no indication that this grant was obtained by organizations other than Kairos Pharma Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL68SHx1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2580731962","title":"Kairos Pharma Provides Shareholder Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731962?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA90DLYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2576059857","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576059857?lang=en_us&edition=fundamental","pubTime":"2025-10-20 21:38","pubTimestamp":1760967480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 09:38 ET (13:38 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2576859939","title":"Kairos Pharma Reports Positive Phase 2 Results for ENV-105 in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2576859939","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576859939?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:01","pubTimestamp":1760961700,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has announced positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105  in patients with metastatic castration-resistant prostate cancer . The results were presented at the annual European Society Medical Oncologists  meeting in Berlin, Germany. The randomized trial, led by Dr. Edwin Posadas, is enrolling up to 100 patients across several cancer centers. Interim analysis showed that the combination of ENV-105 and apalutamide achieved a median progression-free survival of 13.7 months, with clinical benefit observed in 86% of treated patients. Seven out of nine evaluable patients experienced a reduction in PSA levels. ENV-105, a first-in-class CD105 antagonist, is being evaluated for its safety and efficacy in men with prostate cancer resistant to hormone therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLfdr77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2575229756","title":"Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2575229756","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575229756?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:11","pubTimestamp":1760559083,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units  under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. publis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL96f3s8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2574375975","title":"Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2574375975","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574375975?lang=en_us&edition=fundamental","pubTime":"2025-10-09 01:05","pubTimestamp":1759943113,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy has maintained their bullish stance on KAPA stock, giving a Buy rating on September 22. Jason McCarthy has given...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-kairos-pharmas-lead-candidate-env-105-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-kairos-pharmas-lead-candidate-env-105-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2573966947","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2573966947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573966947?lang=en_us&edition=fundamental","pubTime":"2025-10-07 22:57","pubTimestamp":1759849020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2025 10:57 ET (14:57 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2573950582","title":"Kairos Pharma to Present at ESMO Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573950582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573950582?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:28","pubTimestamp":1759840131,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On October 7, 2025, Kairos Pharma announced its selection to present at the European ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-to-present-at-esmo-congress-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-to-present-at-esmo-congress-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","BK4139","KAIR"],"gpt_icon":0},{"id":"2573952440","title":"Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573952440","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573952440?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:00","pubTimestamp":1759838431,"startTime":"0","endTime":"0","summary":"Kairos Pharma Announces Positive Interim Results from Phase 2 Trial of ENV105 in Advanced Prostate Cancer, Set to Present at ESMO 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on October 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL71qk7t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2573952104","title":"Kairos Pharma to Present Positive Safety and Efficacy Data From Phase 2 Prostate Cancer Trial at Esmo 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573952104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573952104?lang=en_us&edition=fundamental","pubTime":"2025-10-07 20:00","pubTimestamp":1759838400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUABYQWSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2568243257","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2568243257","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568243257?lang=en_us&edition=fundamental","pubTime":"2025-09-19 19:26","pubTimestamp":1758281160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 19, 2025 07:26 ET (11:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2568547732","title":"Kairos Pharma Reports Positive Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2568547732","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568547732?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:30","pubTimestamp":1758198652,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. On September 18, 2025, Kairos Pharma announced positive interim efficacy data from its Phase ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-reports-positive-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-reports-positive-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"2568184474","title":"Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of Env105 in Advanced Prostate Cancer With Median Progression Free Survival of Over One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2568184474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568184474?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:00","pubTimestamp":1758196841,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250918:nFWN3V515Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2568416246","title":"Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2568416246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568416246?lang=en_us&edition=fundamental","pubTime":"2025-09-18 02:15","pubTimestamp":1758132914,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., retaining the price target of $4.00. Jason McCarthy has given...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharmas-promising-developments-and-positive-trial-data-reinforce-buy-recommendation-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharmas-promising-developments-and-positive-trial-data-reinforce-buy-recommendation-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"gpt_icon":0},{"id":"2568482357","title":"Kapa Gold Inc. Secures $710,520 Through Warrant Exercise to Bolster Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2568482357","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568482357?lang=en_us&edition=fundamental","pubTime":"2025-09-17 00:41","pubTimestamp":1758040896,"startTime":"0","endTime":"0","summary":"KAPA Gold Inc ( ($TSE:KAPA) ) has provided an update. Kapa Gold Inc. has announced the successful exercise of 3,552,600 warrants at a price of $0.2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kapa-gold-inc-secures-710520-through-warrant-exercise-to-bolster-operations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kapa-gold-inc-secures-710520-through-warrant-exercise-to-bolster-operations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["1OZmain","DUST","BK4139","GDX","NUGT","MGCmain","IAU","518880","159934","SGCmain","SGUmain","GCmain","KAPA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}